Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Liabilities (2019 - 2026)

Insight Molecular Diagnostics' Other Non-Current Liabilities history spans 7 years, with the latest figure at $43.5 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 15.23% to $43.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $43.5 million, a 15.23% increase, with the full-year FY2025 number at $43.5 million, up 15.23% from a year prior.
  • Other Non-Current Liabilities hit $43.5 million in Q4 2025 for Insight Molecular Diagnostics, down from $43.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for IMDX hit a ceiling of $64.6 million in Q1 2022 and a floor of $2.9 million in Q2 2023.
  • Historically, Other Non-Current Liabilities has averaged $31.1 million across 5 years, with a median of $39.3 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 82.31% in 2022 and later surged 1381.81% in 2024.
  • Tracing IMDX's Other Non-Current Liabilities over 5 years: stood at $7.1 million in 2021, then surged by 503.48% to $42.6 million in 2022, then dropped by 5.71% to $40.2 million in 2023, then fell by 6.13% to $37.7 million in 2024, then rose by 15.23% to $43.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for IMDX at $43.5 million in Q4 2025, $43.9 million in Q3 2025, and $40.9 million in Q2 2025.